PALO ALTO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and...
Up to 60% of patients with migraine do not sufficiently respond to triptans.Efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of...
Scilex launched its third commercial product, GLOPERBA® on June 10, 2024.Scilex has officially shipped its recently approved, GLOPERBA® to many national drug/pharmacy chains, as well as independent...
PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and...
Stocking of GLOPERBA® is underway in all of the wholesalers with which Scilex has stocking arrangements throughout the U.S and Scilex expects completion of stocking by Wednesday June 12, 2024.Today,...
Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Gout is a painful arthritic disorder affecting...
PALO ALTO, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or the Company), an innovative revenue-generating company focused on acquiring, developing and...
PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or Company), an innovative revenue-generating company focused on acquiring, developing and...
PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or Company), an innovative revenue-generating company focused on acquiring, developing and...
Scilex management is determined to enhance its stockholders™ value and protect their stockholder rights, and is taking steps to combat manipulative and naked short selling practices in Scilex common...